Urothelial Cancer Overview

Save information for later
Sign Up

Learn About Urothelial Cancer

What is the definition of Urothelial Cancer?
Urothelial cancer, also known as transitional cell carcinoma, affects the kidney (renal) pelvis or ureter (tube) that drains urine from the kidney to the bladder and/or the lining of the inside of the bladder. It is the most common form of bladder cancer and occurs more frequently in men and older adults. The cause of urothelial cancer is unknown; however, some suspected causes are chronic irritation of the kidney from pain medicines, exposure to manufacturing chemicals and dyes, smoking or other tobacco use, past radiation exposure, and parasitic infections.
What are the symptoms of Urothelial Cancer?
Symptoms of urothelial cancer include fatigue, unexplained weight loss, loss of appetite, anemia, constant back pain, flank pain, pelvic pain, urinary urgency, pain, burning, or discomfort when urinating, or blood in urine (hematuria).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Urothelial Cancer?
Treatment for urothelial cancer includes surgery and chemotherapy. Bladder cancer can recur after treatment; therefore, long-term follow-up is necessary.
Who are the top Urothelial Cancer Local Doctors?
Elite in Urothelial Cancer
Dr. Ashish M. Kamat
Urology
Elite in Urothelial Cancer
Dr. Ashish M. Kamat
Urology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances

Ashish Kamat is an Urologist in Houston, Texas. Dr. Kamat is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Elite in Urothelial Cancer
Dr. Sumanta K. Pal
Oncology
Elite in Urothelial Cancer
Dr. Sumanta K. Pal
Oncology

City Of Hope Medical Foundation

1601 Avocado Ave, 
Newport Beach, CA 
949-763-2204
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumanta Pal is an Oncologist in Newport Beach, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Urothelial Cancer
Dr. Guido M. Dalbagni
Urology
Elite in Urothelial Cancer
Dr. Guido M. Dalbagni
Urology

Mskcc Surgery Group

1275 York Ave, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Guido Dalbagni is an Urologist in New York, New York. Dr. Dalbagni is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy. Dr. Dalbagni is currently accepting new patients.

View All Doctors
What are the latest Urothelial Cancer Clinical Trials?
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A, Phase 2. During part A, Phase 2, preliminary efficacy and safety will be assessed, and the recommen...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Who is this study for: Adult patients with Genitourinary Tumors
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2

Summary: This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ...

View All Clinical Trials